Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is scheduled to announce its Q316 earnings results on Tuesday, November 15th. Analysts expect the company to announce earnings of $1.29 per share and revenue of $5.76 billion for the quarter.

Earnings History for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) opened at 40.65 on Monday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $37.82 and a 12 month high of $66.55. The company has a 50-day moving average price of $43.93 and a 200-day moving average price of $50.26. The firm has a market capitalization of $37.15 billion, a price-to-earnings ratio of 27.15 and a beta of 0.73.

A number of analysts have recently weighed in on the company. Bank of America Corp. downgraded Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $48.00 target price for the company. in a research report on Monday, November 7th. HSBC downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and upped their target price for the company from $44.00 to $66.00 in a research report on Friday, November 4th. Credit Suisse Group AG upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “outperform” rating and cut their target price for the company from $59.00 to $52.00 in a research report on Monday, October 31st. They noted that the move was a valuation call. Mizuho downgraded Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and cut their target price for the company from $64.00 to $45.00 in a research report on Monday, October 24th. Finally, Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research report on Wednesday, October 19th. Nine research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and an average price target of $65.44.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. raised its position in shares of Teva Pharmaceutical Industries by 11.9% in the second quarter. Franklin Resources Inc. now owns 41,211,549 shares of the company’s stock valued at $2,070,095,000 after buying an additional 4,389,590 shares during the last quarter. Waddell & Reed Financial Inc. raised its position in shares of Teva Pharmaceutical Industries by 4.9% in the second quarter. Waddell & Reed Financial Inc. now owns 19,358,468 shares of the company’s stock valued at $972,375,000 after buying an additional 896,033 shares during the last quarter. Janus Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries by 14.2% in the second quarter. Janus Capital Management LLC now owns 4,577,851 shares of the company’s stock valued at $229,933,000 after buying an additional 568,998 shares during the last quarter. State of Tennessee Treasury Department purchased a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $25,399,000. Finally, Ontario Teachers Pension Plan Board raised its position in shares of Teva Pharmaceutical Industries by 65.7% in the second quarter. Ontario Teachers Pension Plan Board now owns 1,128,900 shares of the company’s stock valued at $56,705,000 after buying an additional 447,600 shares during the last quarter. Institutional investors and hedge funds own 63.38% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.